24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
AHA News: Understanding the Basics of 'Herd Immunity'Multiple Measures of Social Distancing Required to Slow Coronavirus: StudyCough, Fever, Fatigue? Head to CDC's Online Coronavirus Symptom CheckerThree Countries Have Kept Coronavirus in Check; Here's How They Did ItTrial Finds Acupuncture May Help Prevent MigrainesSevere COVID-19 Might Injure the HeartWhy Are Teens, Millennials Ignoring Coronavirus Warnings?An Expert's Guide to Fact-Checking Coronavirus Info OnlineLivestock, Poultry Safe From Coronavirus: ExpertWuhan Study Shows How Social Distancing Is Saving LivesU.S. Hospital Beds Were Already Maxed Out Before Coronavirus PandemicFDA Warns of Defective EpiPen DangersPoll Finds High Anxiety in the Time of CoronavirusCould Robots Be Deployed to Front Line in Fighting COVID-19?COVID-19 May Force Some Cancer Patients to Delay TreatmentWhat People With Parkinson's Need to Know About COVID-19How to Weather Social Isolation During Coronavirus PandemicCOVID-19 Infection Likely Worse for Vapers, SmokersWhen Arteries Narrow, Chest Pain Can Come Earlier for Women Than MenLoss of Sense of Smell Could Be Early Sign of Coronavirus InfectionMany Drugs Already Approved by FDA May Have Promise Against COVID-19The Other Side of COVID-19: Milder Cases, Healthy RecoveryAs Coronavirus Myths Multiply, Experts Sort Fact From FictionA Third of Americans Ordered to Stay at Home; Summer Olympics Postponed for One YearWeight-Loss Surgery May Cut Risk of Heart Attack, StrokeFDA Warns Americans to Beware of Fake COVID-19 Test KitsTaking Steroids for Rheumatoid Arthritis, IBD? Your Odds for Hypertension May RiseWhat Does a Self-Quarantine Look Like?National Guard Activated in 3 States as U.S. Coronavirus Cases Top 34,000U.S. Coronavirus Cases Pass 26,000, With 1 in 4 Americans Under 'Shelter-in-Place' OrdersRaking Your Leaves to the Edge of Your Yard an Invitation to TicksNew Drug Helps Shrink Inoperable Tumors in KidsCoronavirus Crisis Should Put Elective Surgeries on Hold, Doctors' Group SaysAlmost Half of Coronavirus Patients Have Digestive SymptomsNearly 40% of Hospitalizations in U.S. COVID-19 Cases Involve Adults Under 55Healthy Living at Home to Ward Off CoronavirusWhat You Need to Know About Coronavirus If You Have AsthmaStudy Suggests COVID-19 Might Follow Seasonal PatternTrump Signs Massive Relief Package Into Law as U.S. Coronavirus Cases Reach 10,000AHA News: A Look at Allergies and Heart Health, With Tips to Endure Pollen Season Amid Coronavirus FearsNew Coronavirus Wasn't Made in a Lab, Genomic Study ShowsWho's Most at Risk From Coronavirus?The Most Effective Ways to Kill Coronavirus in Your HomeCoronavirus Cases Hit All 50 States, as U.S. Death Toll Tops 100AHA News: Working Out While Staying Safe During the Coronavirus OutbreakMedical Groups Say Heart Meds Don't Worsen COVID-19 SymptomsBelly Fat Can Lead to a Sudden Attack of Pancreatitis: StudyWith New Boost From Medicare, 'Telemedicine' Steps Up to Fight CoronavirusAnother Study Finds COVID-19 Typically Mild for KidsKeeping Coronavirus Anxiety at Bay
Questions and AnswersLinks
Related Topics

Diabetes

Scientists Spot Antibody That Might Help Diagnose, Treat Autoimmune Disorders

HealthDay News
by -- Robert Preidt
Updated: Feb 12th 2020

new article illustration

WEDNESDAY, Feb. 12, 2020 (HealthDay News) -- Researchers who have pinpointed an antibody linked to life-threatening autoimmune disorders in children say their discovery could lead to faster diagnosis and treatment of these patients.

The investigators identified the myelin oligodendrocyte glycoprotein (MOG) antibody in their study of 535 children with central nervous system demyelinating disorders and encephalitis.

MOG antibodies damage the protective covering (myelin sheath) that surrounds nerve fibers in the brain, optic nerves and spinal cord, which means that messages can't be passed along these nerves.

Of the 116 children who tested positive for MOG antibodies and received appropriate treatment, 85% had complete or near-complete recovery, according to the study published Feb. 10 in The Lancet Neurology journal.

The findings suggest that the MOG antibody is associated with more life-threatening autoimmune conditions than previously thought. These include neuromyelitis optica spectrum disorders and encephalitis, which cause severe brain and nervous system symptoms such as vision loss, muscle weakness and loss of coordination and speech, the researchers said.

This group of neurological disorders can mimic similar conditions like multiple sclerosis (MS), making them difficult to diagnose correctly. Until about 10 years ago, patients with these diseases were thought to have atypical forms of MS, and the prognosis and best treatment methods were unknown.

Over the last 10 years, research has shown that several demyelinating diseases are associated with the MOG-antibody biomarker, and that patients with these diseases often improve with immunotherapy.

However, the best treatment approaches and long-term outcomes remain unclear. This new study suggests that testing for the MOG antibody could help identify the most beneficial treatment for some of these disorders, the study authors said.

"The diagnosis of many of these patients, especially those with encephalitis, would have been missed if it were not for the prospective design of our study," said study co-leader Thais Armangue, from Sant Joan de Deu Children's Hospital at the University of Barcelona, in Spain.

"Identifying these patients is important because most of the children who tested positive for MOG antibodies responded to treatment with immunotherapy," Armangue added in a journal news release.

According to study co-lead author Josep Dalmau, from the University of Barcelona, "Demyelinating diseases in children can be very difficult to distinguish because they present with similar symptoms and imaging features. Correct and early diagnosis allows for treatment with immunosuppressants, rather than the treatments specifically used in MS that are not effective. Moreover, it is important to differentiate between those diseases that do not require chronic treatment and others in which prolonged immunotherapy is needed to improve long-term outcomes."

The study is "a milestone in the understanding of MOG antibody-associated syndromes," Romain Marignier, from the Hopital Neurologique Pierre Wertheimer in France, wrote in an accompanying editorial.

More information

The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases has more on autoimmune diseases.